SciSparc (SPRC) Competitors $5.30 -0.26 (-4.68%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$5.42 +0.12 (+2.17%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. CARM, NXTC, LPTX, BFRG, TXMD, ERNA, BIVI, MTVA, BCDA, and PHIOShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Carisma Therapeutics (CARM), NextCure (NXTC), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), TherapeuticsMD (TXMD), Ernexa Therapeutics (ERNA), BioVie (BIVI), MetaVia (MTVA), BioCardia (BCDA), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Its Competitors Carisma Therapeutics NextCure Leap Therapeutics Bullfrog AI TherapeuticsMD Ernexa Therapeutics BioVie MetaVia BioCardia Phio Pharmaceuticals SciSparc (NASDAQ:SPRC) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Does the media prefer SPRC or CARM? In the previous week, SciSparc had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for SciSparc and 0 mentions for Carisma Therapeutics. SciSparc's average media sentiment score of 0.49 beat Carisma Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the media. Company Overall Sentiment SciSparc Neutral Carisma Therapeutics Neutral Is SPRC or CARM more profitable? SciSparc has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets SciSparcN/A N/A N/A Carisma Therapeutics -254.28%N/A -137.38% Do analysts rate SPRC or CARM? Carisma Therapeutics has a consensus price target of $1.93, suggesting a potential upside of 600.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than SciSparc.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71 Which has preferable valuation and earnings, SPRC or CARM? SciSparc has higher earnings, but lower revenue than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSciSparc$1.31M2.17-$6.28MN/AN/ACarisma Therapeutics$19.63M0.59-$60.48M-$1.56-0.18 Which has more risk and volatility, SPRC or CARM? SciSparc has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Do institutionals and insiders have more ownership in SPRC or CARM? 25.1% of SciSparc shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryCarisma Therapeutics beats SciSparc on 8 of the 14 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.97M$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.18%P/E RatioN/A19.6629.8725.14Price / Sales2.17634.80422.9397.17Price / CashN/A165.0335.9458.58Price / Book0.294.198.105.59Net Income-$6.28M$31.61M$3.26B$265.48M7 Day Performance-6.53%0.95%0.64%1.22%1 Month Performance-19.08%2.90%2.42%0.39%1 Year Performance-20.18%4.11%27.60%23.47% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.4581 of 5 stars$5.30-4.7%N/A-23.5%$2.97M$1.31M0.004News CoverageGap DownCARMCarisma Therapeutics2.3635 of 5 stars$0.34-7.2%$1.93+467.7%-65.6%$14.17M$19.96M-0.2220Positive NewsGap DownNXTCNextCure4.3629 of 5 stars$5.24-5.4%$33.00+529.8%-72.5%$14.02MN/A-0.2590News CoverageEarnings ReportGap DownLPTXLeap Therapeutics1.878 of 5 stars$0.33-1.6%$3.38+910.5%-84.3%$13.84MN/A-0.2040Upcoming EarningsGap DownBFRGBullfrog AI0.898 of 5 stars$1.45-2.7%N/A-44.9%$13.66M$60K-1.794TXMDTherapeuticsMD0.6065 of 5 stars$1.16-0.9%N/A-36.0%$13.42M$1.76M0.00420News CoveragePositive NewsUpcoming EarningsERNAErnexa Therapeutics0.7017 of 5 stars$1.79-6.3%N/A-93.6%$13.17M$580K-0.2210Upcoming EarningsBIVIBioVie0.1771 of 5 stars$6.97-1.8%N/A-86.7%$12.96MN/A-0.0910News CoverageMTVAMetaVia2.4469 of 5 stars$0.63-4.4%$7.50+1,081.8%N/A$12.43MN/A0.008Earnings ReportGap UpBCDABioCardia2.8863 of 5 stars$2.22-3.1%$25.00+1,026.1%-40.2%$12.22M$3K-0.9540Positive NewsUpcoming EarningsPHIOPhio Pharmaceuticals2.5671 of 5 stars$2.54+0.4%$14.00+451.2%-17.9%$12.19MN/A-0.4010Upcoming EarningsGap Down Related Companies and Tools Related Companies CARM Alternatives NXTC Alternatives LPTX Alternatives BFRG Alternatives TXMD Alternatives ERNA Alternatives BIVI Alternatives MTVA Alternatives BCDA Alternatives PHIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
